In 2019, Mesoblast Ltd  (MSB) plans to work diligently with the...

  1. 824 Posts.
    lightbulb Created with Sketch. 44

    In 2019, Mesoblast Ltd  (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategy  


    http://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.61
Change
-0.003(0.15%)
Mkt cap ! $2.041B
Open High Low Value Volume
$1.61 $1.62 $1.57 $2.539M 1.596M

Buyers (Bids)

No. Vol. Price($)
16 32001 $1.61
 

Sellers (Offers)

Price($) Vol. No.
$1.62 53286 21
View Market Depth
Last trade - 11.27am 08/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.